Top

International Urogynecology Journal

Published in:

01-09-2013 | Original Article

Changes in nerve growth factor level and symptom severity following antibiotic treatment for refractory overactive bladder

Authors: G. Vijaya, R. Cartwright, A. Derpapas, P. Gallo, R. Fernando, V. Khullar

Published in: International Urogynecology Journal | Issue 9/2013

Abstract

Introduction and hypothesis

Overactive bladder (OAB) has a multifactorial aetiology, and for some women symptoms may be associated with chronic urothelial inflammation secondary to bacterial colonisation. One marker of such inflammation may be urinary nerve growth factor (NGF). We hypothesised that for women with OAB and urothelial inflammation, urinary NGF would be reduced following antibiotic therapy.

Methods

Women with overactive bladder and urodynamic diagnosis of detrusor overactivity who were refractory to anticholinergics, and had histological evidence of urothelial inflammation were treated with a 6-week course of rotating antibiotics. Urinary NGF was measured by ELISA before and after treatment. Three-day bladder diaries, the Patients’ Perception of Intensity of Urgency Scale, the King’s Health Questionnaire and the Patients’ Perception of Bladder Condition questionnaire were used to assess subjective and objective outcomes of therapy.

Results

Thirty-nine women with refractory DO were recruited. The NGF levels decreased significantly after antibiotic therapy (Wilcoxon signed rank test; p = 0.015). There were significant improvements in daytime frequency, nocturia and urgency (p < 0.05), and 74 % of women reported improvement in perception of their bladder condition.

Conclusions

Urinary NGF is responsive to antibiotic therapy. Women with refractory overactive bladder and elevated NGF may benefit from antibiotic treatment.

Steers WD, Tuttle JB (2006) Mechanisms of disease: the role of nerve growth factor in the pathophysiology of bladder disorders. Nat Clin Pract Urol 3(2):101–110. doi:10.1038/ncpuro0408 PubMedCrossRef

Chuang YC, Fraser MO, Yu Y, Chancellor MB, de Groat WC, Yoshimura N (2001) The role of bladder afferent pathways in bladder hyperactivity induced by the intravesical administration of nerve growth factor. J Urol 165(3):975–979PubMedCrossRef

Zvara P, Vizzard MA (2007) Exogenous overexpression of nerve growth factor in the urinary bladder produces bladder overactivity and altered micturition circuitry in the lumbosacral spinal cord. BMC Physiol 7:9. doi:10.1186/1472-6793-7-9 PubMedCrossRef

Dupont MC, Spitsbergen JM, Kim KB, Tuttle JB, Steers WD (2001) Histological and neurotrophic changes triggered by varying models of bladder inflammation. J Urol 166(3):1111–1118PubMedCrossRef

Kim JC, Park EY, Seo SI, Park YH, Hwang TK (2006) Nerve growth factor and prostaglandins in the urine of female patients with overactive bladder. J Urol 175(5):1773–1776. doi:10.1016/s0022-5347(05)00992-4, discussion 1776PubMedCrossRef

Liu HT, Chen CY, Kuo HC (2010) Urinary nerve growth factor levels in overactive bladder syndrome and lower urinary tract disorders. J Formos Med Assoc 109(12):862–878. doi:10.1016/s0929-6646(10)60133-7 PubMedCrossRef

Cho KJ, Kim HS, Koh JS, Kim JC (2012) Changes in urinary nerve growth factor and prostaglandin E(2) in women with overactive bladder after anticholinergics. Int Urogynecol J. doi:10.1007/s00192-012-1854-4

Liu HT, Lin H, Kuo HC (2011) Increased serum nerve growth factor levels in patients with overactive bladder syndrome refractory to antimuscarinic therapy. Neurourol Urodyn 30(8):1525–1529. doi:10.1002/nau.21118 PubMedCrossRef

Banakhar MA, Al-Shaiji TF, Hassouna MM (2012) Pathophysiology of overactive bladder. Int Urogynecol J 23(8):975–982. doi:10.1007/s00192-012-1682-6 PubMedCrossRef

10.

Garnett S, Swithinbank L, Ellis-Jones J, Abrams P (2009) The long-term natural history of overactive bladder symptoms due to idiopathic detrusor overactivity in women. BJU Int 104(7):948–953. doi:10.1111/j.1464-410X.2009.08535.x PubMedCrossRef

11.

Diamond P, Hassonah S, Alarab M, Lovatsis D, Drutz HP (2012) The prevalence of detrusor overactivity amongst patients with symptoms of overactive bladder: a retrospective cohort study. Int Urogynecol J 23(11):1577–1580. doi:10.1007/s00192-012-1781-4 PubMedCrossRef

12.

Khasriya R, Khan S, Lunawat R, Bishara S, Bignal J, Malone-Lee M, Ishii H, O’Connor D, Kelsey M, Malone-Lee J (2010) The inadequacy of urinary dipstick and microscopy as surrogate markers of urinary tract infection in urological outpatients with lower urinary tract symptoms without acute frequency and dysuria. J Urol 183(5):1843–1847. doi:10.1016/j.juro.2010.01.008 PubMedCrossRef

13.

Walsh CA, Siddins A, Parkin K, Mukerjee C, Moore KH (2011) Prevalence of “low-count” bacteriuria in female urinary incontinence versus continent female controls: a cross-sectional study. Int Urogynecol J 22(10):1267–1272. doi:10.1007/s00192-011-1506-0 PubMedCrossRef

14.

Cartwright R, Srikrishna S, Cardozo L, Robinson D (2011) Validity and reliability of the patient’s perception of intensity of urgency scale in overactive bladder. BJU Int 107(10):1612–1617. doi:10.1111/j.1464-410X.2010.09684.x PubMedCrossRef

15.

Coyne KS, Matza LS, Kopp Z, Abrams P (2006) The validation of the patient perception of bladder condition (PPBC): a single-item global measure for patients with overactive bladder. Eur Urol 49(6):1079–1086. doi:10.1016/j.eururo.2006.01.007 PubMedCrossRef

16.

Tyagi P, Barclay D, Zamora R, Yoshimura N, Peters K, Vodovotz Y, Chancellor M (2010) Urine cytokines suggest an inflammatory response in the overactive bladder: a pilot study. Int Urol Nephrol 42(3):629–635. doi:10.1007/s11255-009-9647-5 PubMedCrossRef

17.

Aloe L, Bracci-Laudiero L, Bonini S, Manni L (1997) The expanding role of nerve growth factor: from neurotrophic activity to immunologic diseases. Allergy 52(9):883–894PubMedCrossRef

18.

Haylen BT, de Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J, Monga A, Petri E, Rizk DE, Sand PK, Schaer GN (2010) An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J 21(1):5–26. doi:10.1007/s00192-009-0976-9 PubMedCrossRef

19.

Moore KH, Simons A, Mukerjee C, Lynch W (2000) The relative incidence of detrusor instability and bacterial cystitis detected on the urodynamic-test day. BJU Int 85(7):786–792PubMedCrossRef

20.

Salvatore S, Serati M, Origoni M, Candiani M (2012) Is overactive bladder in children and adults the same condition? ICI-RS 2011. Neurourol Urodyn 31(3):349–351. doi:10.1002/nau.22223 PubMedCrossRef

21.

Hessdoerfer E, Jundt K, Peschers U (2011) Is a dipstick test sufficient to exclude urinary tract infection in women with overactive bladder? Int Urogynecol J 22(2):229–232. doi:10.1007/s00192-010-1263-5 PubMedCrossRef

22.

Fitzgerald MP, Ayuste D, Brubaker L (2005) How do urinary diaries of women with an overactive bladder differ from those of asymptomatic controls? BJU Int 96(3):365–367. doi:10.1111/j.1464-410X.2005.05632.x PubMedCrossRef

23.

Digesu GA, Khullar V, Cardozo L, Salvatore S (2003) Overactive bladder symptoms: do we need urodynamics? Neurourol Urodyn 22(2):105–108. doi:10.1002/nau.10099 PubMedCrossRef

24.

Latthe PM, Toozs-Hobson P, Gray J (2008) Mycoplasma and ureaplasma colonisation in women with lower urinary tract symptoms. J Obstet Gynaecol 28(5):519–521. doi:10.1080/01443610802097690 PubMedCrossRef

25.

Saini R, Gonzalez RR, Te AE (2008) Chronic pelvic pain syndrome and the overactive bladder: the inflammatory link. Curr Urol Rep 9(4):314–319PubMedCrossRef

26.

Hsiao SM, Lin HH, Kuo HC (2012) The role of serum C-reactive protein in women with lower urinary tract symptoms. Int Urogynecol J 23(7):935–940. doi:10.1007/s00192-012-1715-1 PubMedCrossRef

27.

Apostolidis A, Jacques TS, Freeman A, Kalsi V, Popat R, Gonzales G, Datta SN, Ghazi-Noori S, Elneil S, Dasgupta P, Fowler CJ (2008) Histological changes in the urothelium and suburothelium of human overactive bladder following intradetrusor injections of botulinum neurotoxin type A for the treatment of neurogenic or idiopathic detrusor overactivity. Eur Urol 53(6):1245–1253. doi:10.1016/j.eururo.2008.02.037 PubMedCrossRef

28.

Tauber SC, Nau R (2008) Immunomodulatory properties of antibiotics. Curr Mol Pharmacol 1(1):68–79PubMed

29.

Van Kerrebroeck PE, Kelleher CJ, Coyne KS, Kopp Z, Brodsky M, Wang JT (2009) Correlations among improvements in urgency urinary incontinence, health-related quality of life, and perception of bladder-related problems in incontinent subjects with overactive bladder treated with tolterodine or placebo. Health Qual Life Outcomes 7:13. doi:10.1186/1477-7525-7-13 PubMedCrossRef

30.

Warren JW, Horne LM, Hebel JR, Marvel RP, Keay SK, Chai TC (2000) Pilot study of sequential oral antibiotics for the treatment of interstitial cystitis. J Urol 163(6):1685–1688PubMedCrossRef

Title: Changes in nerve growth factor level and symptom severity following antibiotic treatment for refractory overactive bladder
Authors: G. Vijaya
R. Cartwright
A. Derpapas
P. Gallo
R. Fernando
V. Khullar
Publication date: 01-09-2013
Publisher: Springer London
Published in: International Urogynecology Journal / Issue 9/2013
Print ISSN: 0937-3462
Electronic ISSN: 1433-3023
DOI: https://doi.org/10.1007/s00192-012-2038-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Changes in nerve growth factor level and symptom severity following antibiotic treatment for refractory overactive bladder

Abstract

Introduction and hypothesis

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction and hypothesis

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 9/2013

Management of two synthetic midurethral slings eroded into the urethral lumen

On pelvic reference lines and the MR evaluation of genital prolapse: a proposal for standardization using the Pelvic Inclination Correction System

Urogynecology digest

Diagnosis of female urethral diverticulum using transvaginal contrast-enhanced sonourethrography

Standardization of dynamic magnetic resonance imaging measurements of pelvic organ prolapse: can the PICS line help?

A phase II dose-ranging study of mirabegron in patients with overactive bladder